JUPITER NEUROSCIENCES, INC. 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from __________ to ___________ Commission file number: 001-41265 JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 47-4828381 (State of Incorporation) (IRS Employer ID Number) 1001 North US HWY 1 , Suite 504 Jupiter , FL 33477 (Address of Principal Executive Offices) (561) 406-6154 (Registrant’s Telephone number) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share JUNS The Nasdaq Capital Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 for Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of May 14, 2026, there were 36,281,252 shares of Common Stock, par value $ 0.0001 per share (“Common Stock”) issued and outstanding. TABLE OF CONTENTS Page PART I - FINANCIAL INFORMATION 3 Item 1. Financial Statements (unaudited) 3 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements Of Operations 5 Condensed Consolidated Statements Of Changes In Stockholders’ Equity (Deficit) 6 Condensed Consolidated Statements Of Cash Flows 7 Notes To Condensed Consolidated Financial Statements 8 Item 2. Management’s Discussion And Analysis Of Financial Condition And Results Of Operations. 19 Item 3. Quantitative And Qualitative Disclosures About Market Risk. 25 Item 4. Controls And Procedures 25 PART II - OTHER INFORMATION 26 Item 1. Legal Proceedings 26 Item 1A. Risk Factors 26 Item 2. Unregistered Sales Of Equity Securities And Use Of Proceeds 26 Item 3. Defaults Upon Senior Securities 26 Item 4. Mine Safety Disclosures 26 Item 5. Other Information 26 Item 6. Exhibits 27 Signatures 28 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q for the three months ended March 31, 2026 (the “Quarterly Report on Form 10-Q”) contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this Quarterly Report on Form 10-Q, the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast”, “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seeks,” “should,” “would” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. The forward-looking statements contained in this Quarterly Report on Form 10-Q are based on our current expectations and beliefs concerning future developments and their potential effects on us. These forward-looking statements are not guarantees for future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, those identified below and those discussed in the section titled Risk Factors in this filing and our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2026 (the “Annual Report on Form 10-K”): ● Our substantial amount of indebtedness associated with the convertible promissory notes issued in connection with the Standby Equity Purchase Agreement may adversely affect our cash flow and our ability to operate our business, remain in compliance with debt covenants and make payments on our indebtedness; ● Low trading volume in our common stock may limit or prevent our ability to draw on the Standby Equity Purchase Agreement to pay down the convertible promissory notes; ● We have not generated meaningful revenue from product sales to date, have incurred significant net losses since our inception, and expect to continue to incur significant net losses for the foreseeable future; ● Our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report; ● We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts; ● Raising additional capital may cause substantial dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates; ● Our business and future prospects with the Nugevia brand and our pharmaceutical products are significantly dependent on our exclusive, worldwide license agreement with Aquanova. Any adverse development related to this license agreement could materially and adversely affect our operations, financial condition, and results of operations; ● Clinical drug development involves a lengthy and expensive process with an uncertain outcome. The clinical trials of our product candidate may not demonstrate safety and efficacy to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities or otherwise produce positive results and the results of preclinical studies and early clinical trials may not be predictive of future results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates; ● We have limited resources and are currently focusing the majority of our efforts on developing JOTROL™ for particular indications. As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable; ● We face significant competition and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted; ● We may not be successful in our efforts to develop our proprietary drug delivery platform, JOTROL™, to build a pipeline of indications; ● The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction; ● We may face difficulties from changes to current regulations and future legislation; ● Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees; ● The Company’s failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of its securities; ● The price of our common stock could be subject to rapid and substantial volatility. A “short squeeze” due to a sudden increase in demand for shares of our common stock could lead to extreme price volatility in shares of our common stock. As a relatively small-capitalization company with relatively small public float, we may experience greater stock price volatility, extreme price run-ups, lower trading volume and less liquidity than large-capitalization companies. In addition, if the trading volumes of our common stock are low, persons buying or selling in relatively small quantities may easily influence prices of our common stock. This low volume of trades could also cause the price of our common stock to fluctuate greatly, with large percentage changes in price occurring in any trading day session. Holders of our common stock may also not be able to readily liquidate their investment or may be forced to sell at depressed prices due to low volume trading; ● The effects of the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide from the conflict between Russia and Ukraine as well as the conflict in the Middle East; and ● Other risks and uncertainties, including those listed under the captions “ Organization and Description of Business ,” “ Risk Factors ,” and “ Management’s Discussion and Analysis of Financial Condition and Results of Operations. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. 2 JUPITER NEUROSCIENCES, INC. PART I - FINANCIAL INFORMATION 3 JUPITER NEUROSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) March 31, 2026 December 31, 2025 Assets Current Assets: Cash $ 2,362,749 $ 3,789,342 Accounts receivable - 2,637 Prepaid contracts 766,667 766,667 Inventory, net 148,068 159,790 Other current assets 132,696 106,542 Total current assets 3,410,180 4,824,978 Operating lease right of use asset, net 11,607 23,214 Prepaid contracts, noncurrent 523,014 712,055 Other assets 3,783 3,783 Total assets $ 3,948,584 $ 5,564,030 Liabilities and Stockholders’ Deficit Current Liabilities: Accounts payable and accrued expenses $ 474,636 $ 638,646 Accrued compensation 1,422,612 1,397,357 Accrued interest - 39,829 Deferred revenue - 735 Operating lease liability 8,508 21,247 Convertible notes payable, fair value 4,824,411 5,298,068 Refund liability 1,874 - Total current liabilities 6,732,041 7,395,882 Total liabilities 6,732,041 7,395,882 Commitments and Contingencies (Note 7) - Stockholders’ Deficit: Series A preferred stock, par value $ 0.0001 ; 5,000,000 shares authorized, nil shares issued and outstanding - - Common stock, par value $ 0.0001 ; 500,000,000 and 125,000,000 shares authorized, respectively; 36,281,352 and 34,446,455 issued and outstanding, respectively 3,628 3,444 Additional paid in capital 33,941,899 32,831,730 Accumulated deficit ( 36,728,984 ) ( 34,667,026 ) Total stockholders’ deficit ( 2,783,457 ) ( 1,831,852 ) Total liabilities and stockholders’ deficit $ 3,948,584 $ 5,564,030 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 JUPITER NEUROSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) For the Three Months Ended For the Three Months Ended March 31, 2026 March 31, 2025 Product Revenues, net $ 18,652 $ - Cost of goods sold 4,362 - Gross Profit $ 14,290 $ - Expenses: Research and development 411,049 466,745 General and administrative 1,566,241 1,071,258 Total operating expenses 1,977,290 1,538,003 Operating loss ( 1,963,000 ) ( 1,538,003 ) Other Income (Expenses): Interest income 18,404 10,365 Gain on change in fair value of convertible notes 1,282 - Interest expense ( 118,644 ) ( 1,229 ) Total other expenses, net ( 98,958 ) 9,136 Net loss $ ( 2,061,958 ) $ ( 1,528,867 ) Net loss per common share: Basic and Diluted $ ( 0.06 ) $ ( 0.05 ) Weighted average number of common shares outstanding: Basic and Diluted 35,255,588 33,103,860 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 5 JUPITER NEUROSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT ) (Unaudited) Shares Amount in Capital Deficit Deficit Common Stock Additional Paid Accumulated Total Stockholders’ Shares Amount in Capital Deficit Deficit December 31, 2024 33,103,860 $ 3,310 $ 30,190,827 $ ( 26,022,129 ) $ 4,172,008 Stock-based compensation - - 421,454 - 421,454 Net operating loss - - - ( 1,528,867 ) ( 1,528,867 ) March 31, 2025 33,103,860 $ 3,310 $ 30,612,281 $ ( 27,550,996 ) $ 3,064,595 Common Stock Additional Paid Accumulated Total Stockholders’ Shares Amount in Capital Deficit Deficit December 31, 2025 34,446,455 $ 3,444 $ 32,831,730 $ ( 34,667,026 ) $ ( 1,831,852 ) December 31, 2025 34,446,455 $ 3,444 $ 32,831,730 $ ( 34,667,026 ) $ ( 1,831,852 ) Stock-based compensation - - 454,242 - 454,242 Shares issued for exercise of stock options 675,000 68 5,439 - 5,507 Issuance of common stock for payment of notes and interest 995,975 100 496,291 - 496,391 Shares issued for conversion of convertible notes 113,922 11 107,452 - 107,463 Shares issued for service agreement 50,000 5 46,745 - 46,750 Net operating loss - - - ( 2,061,958 ) ( 2,061,958 ) March 31, 2026 36,281,352 $ 3,628 $ 33,941,899 $ ( 36,728,984 ) $ ( 2,783,457 ) March 31, 2026 36,281,352 $ 3,628 $ 33,941,899 $ ( 36,728,984 ) $ ( 2,783,457 ) The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 6 JUPITER NEUROSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) March 31, 2026 March 31, 2025 Cash Flows from Operating Activities: Net Loss $ ( 2,061,958 ) $ ( 1,528,867 ) Adjustments to reconcile net loss to net cash used in operating activities: Gain on change in fair value of convertible notes ( 1,282 ) - Interest expense paid through sale of common stock 131,479 - Amortization of prepaid contracts 189,041 189,041 Stock-based compensation 500,992 421,454 Change in operating lease right of use asset and lease liabilities ( 1,132 ) ( 659 ) Decreases (increases) in operating assets and liabilities: Accounts receivable 2,637 - Prepaid contracts - ( 24,106 ) Decrease in inventory 11,722 - Other current assets ( 26,154 ) - Accounts payable and accrued expenses ( 164,010 ) ( 113,552 ) Accrued compensation 25,255 ( 7,435 ) Deferred revenue ( 735 ) - Refund liability 1,874 - Accrued interest ( 39,829 ) 1,083 Net cash used in operating activities ( 1,432,100 ) ( 1,063,041 ) Cash Flows from Financing Activities: Proceeds from exercise of stock options 5,507 - Net cash provided by financing activities 5,507 - Net Change in Cash ( 1,426,593 ) ( 1,063,041 ) Beginning of period 3,789,342 3,769,510 End of period $ 2,362,749 $ 2,706,469 Supplemental disclosure of cash flow information: Cash paid for interest $ - $ 146 Schedule of Non-Cash Investing and Financing Activities: Stock issued in connection with service agreement $ 46,750 $ - Payment of convertible note from issuance of common stock $ 472,375 $ - Stock issued in connection with interest payment $ 131,479 $ - The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 7 JUPITER NEUROSCIENCES, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2026 Note 1 – Organization and Description of Business Jupiter Neurosciences, Inc. (the “Company”) is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company incorporated in Delaware in January 2016. The Company is advancing a therapeutic pipeline targeting central nervous system (“CNS”) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL ™ , the Company’s proprietary, enhanced resveratrol formulation that has demonstrated potential for significantly improved bioavailability. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a planned Phase IIa clinical study in Parkinson’s disease. The Company’s Nugevia product line brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. JOTROL™ has the potential to deliver a therapeutically effective dose of resveratrol in the blood stream, using a unique patented micellar formulation, without causing gastrointestinal side effects. We expect JOTROL™, based on the results of our Phase I study, will resolve the major obstacle of resveratrol’s poor bioavailability, which has been documented in various scientific articles describing previously conducted human trials with resveratrol as well as preclinical trial results in mice and rats. Standby Equity Purchase Agreement On October 24, 2025, the Company entered into a Standby Equity Purchase Agreement, pursuant to which the Company has the right to sell to an investor up to $ 20.0 million of its common stock, par value $ 0.0001 per share, subject to certain limitations and conditions. See Note 5 – Convertible Debt and Derivative Liability for further details. Nasdaq Minimum Bid Price Compliance On February 26, 2026, the Company received two written notices from the Listing Qualifications Department of Nasdaq notifying the Company that (i) the listing of the Company’s Common Stock was not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price of the Common Stock was less than $ 1.00 per share for the previous 30 consecutive business days, and (ii) for the 30 consecutive business days ended February 26, 2026, the Company’s market value of listed securities closed below the $ 35 million threshold required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until August 25, 2026, to regain compliance by maintaining a minimum closing bid price of at least $ 1.00 per share for a minimum of 10 consecutive business days. 8 Note 2 – Significant Accounting Policies Basis of presentation, Liquidity and Management’s Plans The accompanying condensed financial statements of the Company have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”). U.S. GAAP contemplates the continuation of the Company as a going concern. For the three months ended March 31, 2026, the Company had net revenues from product sales of $ 18,652 , incurred a net loss of $ 2,061,958 and had negative cash flows of $ 1,426,593 , and a cumulative net loss since inception totaling $ 36,728,984 . In management’s opinion, these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the date of this report. The Company plans to finance future operations with proceeds from equity securities, grant awards and strategic collaborations. However, there is no assurance that the Company will be able to effect transactions on commercially reasonable terms, if at all. Business Segment Business segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the Company’s Chief Operating Decision Maker (“CODM”) and relied upon when making decisions regarding resource allocation and assessing performance. When evaluating the Company’s financial performance, the CODM reviews total revenues, total expenses, and expenses by functional classification, using this information to make decisions on a company-wide basis. Effective October 1, 2025, the Company operates through two reportable segments: (i) premium nutritional supplements, and (ii) pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. Use of Estimates Preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and other assumptions, which include both quantitative and qualitative assessments that it believes to be reasonable under the circumstances. Significant estimates during the three months ended March 31, 2026 and 2025, respectively, include valuation of stock-based compensation, uncertain tax positions, the valuation of debt instruments, and the valuation allowance on deferred tax assets. Cash The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company maintains its cash balances with high-credit-quality financial institutions. At times, such balances may exceed federally insured limits provided by the Federal Deposit Insurance Corporation (“FDIC”). In 2025, the Company has implemented a deposit insurance program in the Company’s primary account, whereby funds in excess of FDIC insurance limits are insured. The Company did not have any cash balances that exceeded the FDIC limit of $ 250,000 . 9 Inventory Inventory is stated at the lower of cost or net realizable value, with cost determined using the first-in, first-out method. The Company evaluates inventory for excess or obsolescence based on forecasted demand and records reserves as necessary. As of March 31, 2026 and December 31, 2025, inventory totaled $ 148,068 and $ 159,790 , respectively. Revenue Recognition The Company recognizes revenue when control of its products is transferred to customers, generally upon shipment or delivery, depending on the terms of the arrangement. Revenue is recorded net of estimated variable consideration, including product returns, rebates, discounts, and other allowances, based on historical experience and other relevant factors. The Company evaluates whether it is the principal or agent in its arrangements and records revenue on a gross or net basis accordingly. Shipping and handling activities are considered fulfilment activities, and the related costs are included in cost of goods sold. Prepaid Contracts Prepaid contracts generally represent service agreements which the Company would receive services over a period of time and are expensed as the services are received. The Company’s prepaid contracts are related to service agreements that span over three years; therefore the expense will be recognized over the three year term. See further discussion in Note 6 - Stockholders’ Equity. Research and Development Research and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, monitoring visits, clinical site activations, or information provided to us by our vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. Income Taxes The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the years in which temporary differences are expected to be settled, is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. As of March 31, 2026 and December 31, 2025, the Company concluded that a full valuation allowance is necessary for the net deferred tax assets. Loss Per Share of Common Stock Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which would result in the issuance of incremental shares of common stock, as calculated using the treasury method. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation. 10 As of March 31, 2026, there were 1,626,037 restricted stock units and 11,051,093 stock options outstanding. These securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive. As of December 31, 2025, there were 1,626,037 restricted stock units and 11,726,093 stock options. These securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive. Stock-Based Compensation The grant date fair value of stock-based awards issued to employees, non-employees and members of the board of directors, determined using the Black-Scholes option pricing model and ratably expensed over the requisite service period, which is generally the vesting term of the award. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock, risk-free interest rates and future dividend yields. Clinical Trial Expenses When applicable in preparing financial statements, the Company estimates clinical trial-related expenses based on contracts with vendors, clinical sites, and consultants. Because payment timing often differs from service delivery, the Company records expenses according to actual service performance and trial progression, using discussions with internal staff and external providers. Estimates are periodically adjusted as actual results become known. Accurate accruals depend on timely reporting from third-party vendors, and differences between estimated and actual expenses, though not expected to be significant, may occur. Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 5 - Convertible Debt and Derivative Liability . 11 Convertible Notes with Embedded Derivative Liabilities The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of common stock at a fixed discount to the price of the common stock at or around the time of conversion upon certain trigger events. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives. This accounting treatment requires that the carrying amount of any derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either other income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value at the conversion, repayment, or exercise date and then the related fair value amount is reclassified to other income or expense as part of gain or loss on debt extinguishment. Leases Operating lease right-of-use (“ROU”) assets and related operating lease liabilities are recognized based on the present value of future minimum lease payments over the expected term of the lease after taking into account the likelihood of renewals and extensions at inception. In the event an implicit interest rate is not present in the lease agreement, the Company utilizes its incremental borrowing rate at lease inception in order to determine the present value. Short term leases with an initial term of less than twelve months are expensed as incurred. Note 3 – Related Party Transactions As of March 31, 2026 and December 31, 2025, $ 84,105 and $ 64,105 , respectively, were payable to Titan Advisory Services LLC (“Titan”), a company wholly owned by our Chief Financial Officer, pursuant to a Master Services Agreement (“MSA”) dated December 31, 2022. Under the MSA, Titan provides executive finance and corporate support services to the Company, including service by Saleem Elmasri as Chief Financial Officer. Note 4 – Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following: Schedule of Accounts Payable and Accrued Expenses March 31, 2026 December 31, 2025 Accounts payable $ 92,383 $ 131,130 Professional fees 338,901 467,167 License fee 18,750 - Credit cards 24,602 40,349 Total accounts payable and accrued expenses $ 474,636 $ 638,646 Accrued compensation of $ 1,422,612 and $ 1,397,357 as of March 31, 2026 and December 31, 2025, respectively, includes accrued salaries and health benefits to executives since inception and board fees. Since inception, executive salaries have been paid in cash when the Company’s cash flow has permitted such payment and unpaid salaries related to 2022 and 2023 remain unpaid. Note 5 – Standby Equity Purchase Agreement and Convertible Debt Standby Equity Purchase Agreement and 2025 Convertible Promissory Notes On October 24, 2025, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) and related Registration Rights Agreement with YA II PN, Ltd. (“Yorkville”), providing the Company the right, but not the obligation, to sell up to $ 20.0 million of common stock from time to time, subject to customary conditions, including an effective resale registration statement. 12 In connection with the SEPA, Yorkville agreed to provide up to $ 6.0 million of pre-paid advances via convertible promissory notes (the “Convertible Notes”). On October 27, 2025, the Company received $ 3,720,000 and issued a $ 4.0 million note ( 7 % original issue discount, “OID”). A second $ 1,860,000 tranche was received in December 2025, upon registration effectiveness and receipt of stockholder approval, against a $ 2.0 million note ( 7 % OID). The Convertible Notes bear interest at 8 % (increasing to 18 % upon default), mature on October 24, 2026 , and are convertible at $ 1.50 per share, subject to proportional anti-dilution and price-protection adjustments (not below a contractual floor). Beginning January 7, 2026, and monthly thereafter, the Company must repay one-tenth (1/10) of the then-outstanding principal plus accrued interest (a 5% premium applies to cash repayments). Instalments may be satisfied via SEPA advances without the premium, and SEPA proceeds must be applied first to repay the Convertible Notes until they are repaid in full. As consideration for Yorkville’s commitment to purchase common stock at the Company’s direction pursuant the SEPA, the Company (i) paid to Yorkville a cash “structuring fee” in the amount of $ 25,000 and (ii) upon execution of the SEPA, issued to Yorkville 131,909 Commitment Shares, which have a total aggregate dollar value equal to $200,000, or 1.0% of Yorkville’s $20.0 million aggregate purchase commitment under the SEPA (each Commitment Share valued at approximately $1.5162 per share, representing the VWAP on October 23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the nearest whole share) . On February 20, 2026, the Company and Yorkville entered into an Omnibus Amendment (the “Amendment”). Among other changes, the Amendment revises the terms of the Convertible Notes to defer the commencement of monthly instalment payments to April 1, 2026, effectively providing an extension of approximately three months. The Convertible Notes include features that allow for settlement through either (i) cash repayment or (ii) issuance of common stock at variable or fixed conversion prices, subject to certain contractual terms, including a floor price and instalment-based repayment structure. The Convertible Notes are classified as a Level III liability within the fair value hierarchy, as their valuation is based on significant unobservable inputs and assumptions. The Company elected the fair value option for the Convertible Notes upon issuance. As such, the Convertible Notes are measured at fair value at inception and remeasured at each reporting date, with changes in fair value recognized in earnings. The fair value of the Convertible Notes was determined using a Monte Carlo simulation model. This valuation approach incorporates multiple potential stock price paths over the contractual term, the Company’s ability to settle in shares or cash, the note holder’s ability to convert at a fixed price, variable conversion features tied to market prices, and contractual floors and share caps. The model simulates a large number of potential outcomes and calculates the expected fair value based on probability-weighted results. The Convertible Notes accounted for under the fair value election are each debt host financial instruments containing embedded features wherein the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the Convertible Notes are recorded as a component of Other (expense) income in the consolidated statements of operations, except that the change in estimated fair value attributable to a change in the instrument-specific credit risks is recognized as a component of other comprehensive income. The instrument specific credit risk associated with the Convertible Notes was de minimis. As a result of electing the fair value method, issuance costs related to the Convertible Notes, including the structuring fee and the commitment fee were expensed as incurred. The following key assumptions were used in the Monte Carlo Simulation valuation at each measurement date: Schedule of Fair Value Asset Measuring Non-recurring Basis Assumption December 31, 2025 March 31, 2026 Stock Price (VWAP) $ 0.99 $ 0.33 Volatility ~ 65 % ~ 75 % Risk-Free Rates 3.4 % – 4.7 % 3.7 % – 4.8 % Volatility was estimated using a combination of the Company’s historical volatility and that of comparable publicly traded companies. 13 As of December 31, 2025, the fair value of the Convertible Notes was $ 5,298,068 . As of March 31, 2026, the fair value of the Convertible Notes was $ 4,824,411 . Changes in fair value during the period were recognized in the Statements of Operations as Gain on change in fair value of convertible notes. The original issue discounts totaling $ 420,000 were incorporated into the initial and subsequent fair value measurements of the Convertible Notes. For the three months ended March 31, 2026, the Company recognized a net gain on change in fair value of Convertible Notes of $ 1,282 . For the three months ended March 31, 2026, the Company incurred interest expense of $ 118,610 and paid $ 124,026 in interest and $ 372,375 in principal. These payments were funded through the sale of 995,975 shares of common stock at an average price of $ 0.84 per share and the issuance of common stock under the SEPA. Additionally, $ 100,000 of principal and $ 7,452 of accrued interest related to the 2025 Convertible Notes were settled through the conversion of 113,922 shares of common stock at a conversion price of $ 0.94 per share. As of December 31, 2025, the Company incurred $ 61,723 of interest expense and paid $ 22,251 through the sale of 20,000 shares of common stock at an average price of approximately $ 1.11 through the SEPA. As of December 31, 2025, $ 39,829 is accrued in Accrued interest on the Company’s balance sheets. For the three months ended March 31, 2026, we have issued and sold approximately 1.1 million shares of common stock to Yorkville pursuant to the SEPA, including shares of common stock issued in connection with the settlement of Prepaid Advances and upon conversion of the Convertible Notes, for aggregate net proceeds to us of $ 603,854 . As of March 31, 2026, we have issued and sold approximately 1.1 million shares of common stock to Yorkville pursuant to the SEPA, including shares of common stock issued in connection with the settlement of Prepaid Advances and upon conversion of the Convertible Notes, for aggregate net proceeds to us of $ 625,748 . As of March 31, 2026, the outstanding principal balance on the Convertible Notes is $ 5,527,625 . A summary of activity of the Convertible Notes, which represent the Level III fair value measurements, is presented below: Schedule of Summary of Activity and Fair Value Measurement Notes Balance at December 31, 2025 $ 5,298,068 Repayments ( 472,375 ) Fair value change ( 1,282 ) Balance at March 31, 2026 $ 4,824,411 Note 6 – Stockholders’ Equity (Deficit) Common Stock The Company is authorized to issue 500,000,000 shares of common stock and 5,000,000 shares of preferred stock. The Company had 36,281,352 shares of common stock issued and outstanding as of March 31, 2026. There was no preferred stock issued and outstanding as of March 31, 2026. During the three months ended March 31, 2026, the Company issued 50,000 shares of Common Stock, with an aggregate fair value of $ 46,750 , as consideration for services rendered related to media and investor relations activities, strategic communications support, enhancement to the Company’s market visibility and shareholder engagement. The fair value of the shares issued was determined based on the market price of the Company’s Common Stock at the date of issuance and is included in general and administrative expenses in the accompanying condensed consolidated statement of operations. 14 Service Agreement On June 3, 2024, The Company entered into service agreements with three separate entities, each with a 36-month term. In connection therewith the Company issued an aggregate of 3,487,500 restricted shares of Common Stock, 1,162,500 ratably to each entity with an aggregate fair value at issuance totaling $ 4,638,375 which were registered upon the closing of the IPO in December 2024. In addition, each of the entities agreed to and ultimately purchased 37,500 shares of the Company’s Common Stock at a purchase price of $ 1.33 per share prior to the effective date of the IPO, resulting in aggregate proceeds of $ 150,000 . Pursuant to the agreements, the counterparties are obligated to perform certain services, as defined, and the Company is recognizing the fair value of the issued restricted shares as compensation expense over the 36-month term, the requisite service period. During the three months ended March 31, 2026 and 2025, the Company recorded compensation expense of $ 381,233 in each period, related to the agreement, which is included in general and administrative expenses in the accompanying condensed consolidated statements of operations. Stock Options The Company grants stock awards to officers, employees, directors, and consultants pursuant to its 2021 Equity Incentive Plan (“the Plan”). A summary of activity for the three months ended March 31, 2026 is presented below: Schedule of Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of December 31, 2025 11,726,093 $ 1.02 5.4 $ 1,772,167 Granted - - Exercised ( 675,000 ) 0.01 Forfeited - - Outstanding as of March 31, 2026 11,051,093 $ 1.10 5.5 $ - Exercisable as of March 31, 2026 10,258,811 $ 1.09 5.2 $ - The following table summarized information about employee stock options outstanding as of March 31, 2026: Schedule of Employee Stock Options Outstanding Outstanding Options Vested Options Exercise Price Number Outstanding at March 31, 2026 Weighted Average Remaining Life Number Exercisable at March 31, 2026 Weighted Average Remaining Life $ 0.74 1,657,560 2.82 1,657,560 2.82 $ 0.80 2,783,243 3.04 2,783,243 3.04 $ 0.97 250,000 9.17 135,868 9.17 $ 1.19 357,448 9.26 - - $ 1.23 484,657 9.68 163,955 9.44 $ 1.33 5,461,935 7.08 5,461,935 6.83 $ 2.16 56,250 5.46 56,250 5.21 11,051,093 5.51 10,258,811 5.22 For the three months ended March 31, 2026, the Company recognized stock-based compensation expense of $ 500,992 , consisting of $ 454,242 related to stock options and $ 46,750 related to shares issued for services. 15 Note 7 – Commitments and Contingencies Legal Matters In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to, among other things, intellectual property, commercial arrangements, employment, and regulatory matters. While the outcome of these proceedings and claims cannot be predicted with certainty, as of March 31, 2026, we were not party to any material legal or arbitration proceedings. No governmental proceedings are pending or, to our knowledge, contemplated against us. Office Lease On May 1, 2021, the Company entered into a 61 -month operating lease for office space for a base rent of $ 3,783 subject to a 3 % yearly escalation. As of March 31, 2026 and December 31, 2025, the Company’s operating lease right-of-use asset, net (ROU) is $ 11,607 and $ 23,214 , respectively, and the total lease liability is $ 8,508 and $ 21,247 , respectively, based on an incremental borrowing rate of 0.81 % at lease inception. Schedule of Operating Lease Right-of-use Asset and Liability March 31, December 31, 2026 2025 Operating lease right-of-use asset (“ROU”) is summarized below: Office lease ROU $ 236,009 $ 236,009 Less accumulated reduction ( 224,402 ) ( 212,795 ) Balance of ROU, net $ 11,607 $ 23,214 Operating lease liability related to the ROU asset is summarized below: Office lease liability $ 236,009 $ 236,009 Reduction of lease liability ( 227,501 ) ( 214,762 ) Total $ 8,508 $ 21,247 Future minimum lease liability payments under the non-cancellable operating lease at March 31, 2026 and December 31, 2025 are as follows: Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease Reminder of fiscal year 8,516 21,290 Total lease payments 8,516 21,290 Less: imputed interest ( 8 ) ( 43 ) Total lease liabilities $ 8,508 $ 21,247 Current operating lease liabilities 8,508 21,247 Non-current operating lease liabilities - - Total lease liabilities $ 8,508 $ 21,247 16 Consulting Agreements The Company utilizes various consultants and advisors for clinical research, scientific advisory services and business strategies. Each consultant has an executed agreement in place defining term, compensation, duties, confidentiality, intellectual property. The majority of the agreements have a 2 -year term. Agreements are evaluated for renewal upon expiration. Bonus provisions are at the discretion of the Company’s Board of Directors and are granted on an individual agreement basis. On December 15, 2024, the Company entered into a Strategic Services Agreement (the “Dominant Treasure Agreement”) with Dominant Treasure Health Company Limited (“Dominant Treasure”). Pursuant to the terms of the Dominant Treasure Agreement, Dominant Treasure agreed to provide certain services to the Company to assist the Company in accelerating the Company’s desire to get its products developed and distributed in the Southeast Asian market. In exchange for Dominant Treasure’s services pursuant to the Dominant Treasure Agreement, the Company agreed to pay Dominant Treasure a one-time payment of $ 2,300,000 . In addition, if Dominant Treasure is involved in generating negotiations and conclusion of a distribution agreement for the Company in the countries of China (including Hong Kong), Singapore and Malaysia, the Company will pay Dominant Treasure a success fee of 5 % of any upfront and/or milestone payments to be received by the Company. If such an agreement will include a royalty payment to the Company, Dominant Treasure will receive 5 % of such royalty payment. The Dominant Treasure Agreement has a term of 36 months and may be terminated at any time upon mutual agreement of the parties. The one-time payment of $ 2,300,000 was accounted for as a prepaid contract and will be expensed over a three-year period. For the three months ended March 31, 2026 and 2025, the Company recorded consulting expense of $ 189,041 in each period related to the Dominant Treasure agreement. Licensing and Royalty Agreements - Aquanova AG On September 13, 2016, the Company entered into a Development, Collaboration and License Agreement (“License Agreement”) with Aquanova AG, a German company in the field of development, manufacturing and selling of colloidal formulas. The License Agreement resulted in the creation of the pharmaceutic product, JOTROL™. The Chief Scientific Officer of the Company and Aquanova’s founder, former CEO, and lead scientist, Darius Benham, are the joint inventors of JOTROL™. Aquanova is the assignee on the patents in the United States, the European Union, China and Japan whereas the Company is obligated to maintain the patents. The License Agreement grants ownership to the Company for regulatory approvals and the sole and exclusive worldwide right to develop, manufacture and commercialize all products, including JOTROL™. Aquanova is granted the exclusive license to conduct formulation development and manufacturing. The License Agreement also defines fees owed to Aquanova for product and formulation development and licensing of the products. The Company is required to pay Aquanova an annual license fee of $ 75,000 upon acceptance of the product formulation by both parties, with the license fee requirement ending in the year of marketing authorization approval (“MMA”) in a single territory. MMA has not yet been received as of the period ended March 31, 2026. Upon receipt of approval of the MMA in each territory (e.g., United States, European Union, China, Japan), the Company will pay $ 200,000 to Aquanova per territory in which an MMA approval is received, up to a maximum of $ 600,000 . The Company shall pay Aquanova a royalty of 5 % of net sales in each territory through the later of ten years after the first commercial sale, the first date there is no valid claim within the Aquanova patent rights, or the date of expiration of the MMA in each territory. There is an option (exercisable by either party) to require the Company to pay a one-time royalty of $ 3,000,000 within 180 days of United States marketing approval, with subsequent royalty payments reduced to 1.25 %, in accordance with the terms set forth above. As of March 31, 2026 and December 31, 2025, $ 18,750 and $ 0 of accrued license fees are included in accounts payable and accrued expenses on the balance sheet, respectively. Research and Development Service Providers In addition to the services received under the licensing agreements noted above, a substantial portion of the research and development (“R&D”) expense included in the statement of operations is incurred pursuant to short term service and consulting agreements with third party providers for research, development, testing and manufacturing services. The agreements generally provide termination, at any time by either party without cause, upon a 30-day written notice, unless otherwise disclosed below. There are no pending milestone payments due as of March 31, 2026. Note 8 – Segment Report The Company’s Chief Executive Officer serves as the Chief Operating Decision Maker (“CODM”). The CODM evaluates financial performance and makes resource allocation decisions based on the operating results of the Company’s reportable segments. Effective October 1, 2025, the Company operates through two reportable segments under ASC 280, Segment Reporting: (i) premium nutritional supplements, and (ii) pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. 17 Premium Nutritional Supplements This segment includes all activities related to the commercialization and sale of the Company’s Nugevia product line. Activities within this segment primarily consist of marketing, distribution, sales, customer support, and related supply chain management associated with Nugevia products. Pharmaceutical Operations This segment includes all activities related to the research, development, and regulatory advancement of JOTROL™, the Company’s proprietary resveratrol-based therapeutic candidate, which is being developed to address unmet medical needs and improve patient outcomes. Activities within this segment primarily consist of clinical development, regulatory, manufacturing development, intellectual property protection, and related research and development functions. The CODM assesses segment performance and allocates resources based on segment net loss (income), which represents the primary measure of profit or loss reviewed. The CODM does not evaluate segments using discrete asset or liability information. Accordingly, total assets are reported on a consolidated basis in the accompanying consolidated balance sheets. Allocation Methodology Expenses are attributed to each reportable segment based on the nature of the activity and the function to which the expense relates. Costs that are directly identifiable with a specific segment are recorded to that segment. Selling, general and administrative expenses that benefit both segments are allocated using reasonable and consistently applied methodologies that reflect the estimated level of effort or resources consumed by each segment. These allocation methodologies may include time and effort analyses, headcount, relative revenue, or other activity-based measures, depending on the underlying cost driver. The allocation methodologies are reviewed periodically and refined as necessary to reflect changes in the business. The Company believes such allocations are reasonable and consistent with the manner in which the CODM evaluates segment performance and makes resource allocation decisions. Corporate and other expenses consist primarily of public company costs (including board, investor relations, and SEC reporting expenses), certain executive compensation, certain stock-based compensation, interest income (expense), other income (expense), and income taxes. These costs are not allocated to reportable segments because they are not included in the measures reviewed by the CODM for purposes of assessing segment performance. Segment information for the three months ended March 31, 2026 is presented below: Schedule of Segment Information Pharmaceutical Operations Premium Nutritional Supplements Total Reportable Segments Corporate / Other Consolidated Total Revenue - 18,652 18,652 - 18,652 Cost of goods sold - 4,362 4,362 - 4,362 Research and development 411,049 - 411,049 - 411,049 Selling, general and administrative 202,308 469,881 672,189 894,052 1,566,241 Segment net loss ( 613,357 ) ( 455,591 ) ( 1,068,948 ) ( 894,052 ) ( 1,963,000 ) Other interest income (expense), net - - - ( 98,958 ) ( 98,958 ) Net loss ( 613,357 ) ( 455,591 ) ( 1,068,948 ) ( 993,010 ) ( 2,061,958 ) Note 9 – Subsequent Events On April 2, 2026, the Company granted stock options to purchase 100,000 shares of common stock to each of two consultants. Twenty-five percent ( 25 %) of the shares underlying each option vested on the grant date. The remaining shares vest in equal monthly installments of 4.167 % on each monthly anniversary of the grant date, such that each option will be fully vested on the second anniversary of the grant date, subject to the consultant’s continued service through each applicable vesting date. On April 30, 2026, the Company granted 100,000 restricted stock units to a consultant. Twenty-five percent ( 25 %) of the restricted stock units vested on the grant date. The remaining restricted stock units vest in four equal annual installments over the following four years. 18 ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial information and related notes included in our Annual Report on Form 10-K. Unless the context otherwise requires references to, “JNS,” “we,” “us,” “our,” or the “Company” refers to Jupiter Neurosciences, Inc. Business Overview Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company is advancing a therapeutic pipeline targeting central nervous system (“CNS”) disorders and rare diseases, while also expanding into the consumer market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated potential for significantly improved bioavailability in an FDA regulated Phase I study. The Company’s therapeutic development pipeline is focused broadly on CNS disorders, presently with a Phase IIa clinical study in Parkinson’s disease. The Company’s Nugevia product line brings cutting edge science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company completed preclinical studies at the University of Miami for Parkinson’s Disease in 2021. These studies used a validated mouse model to mimic human disease characteristics. JOTROL™ demonstrated consistent improvements in motor coordination, endurance, and strength across multiple endpoints in a validated Parkinson’s disease model, with statistically significant benefits versus untreated disease controls. The promising results have led the Company to initiate a Phase IIa clinical trial for Parkinson’s Disease, which received final IND approval by the FDA in November of 2025 and is expected to start in the second quarter of 2026, with results anticipated 12 months later. The Company also aims to investigate other CNS indications, such as Mild Cognitive Impairment (“MCI”) and Alzheimer’s disease, following the Parkinson’s study. The Company believes, based on pre-clinical and clinical studies, that high doses of resveratrol are necessary for potential therapeutic effects. Currently available resveratrol products cannot reach these levels without causing severe gastrointestinal side effects. Human studies evaluating resveratrol in Alzheimer’s patients (Turner et al 2015) and Friedreich’s Ataxia patients (Yu et al 2015) indicate the concentration of resveratrol at its peak (CMax) measured in blood plasma should be 300 ng/ml or higher for a potential therapeutic effect. A Phase 1 study with 500mg of resveratrol as a maximum dose in the JOTROL™ formulation showed levels of resveratrol exceeding 800 ng/ml without generating any severe adverse events (AAPS Open 2022). Resveratrol was shown in the Turner Alzheimer’s study to cross the blood-brain barrier, possibly indicating a potential for positive effects on oxidative stress and inflammation. Subsequent analysis published in Molecular Science 2025 (Mousa et al) further indicates that resveratrol may have an impact on neurodegeneration and neuroinflammation in Alzheimer’s patients. Over the past two years, JOTROL™ has garnered significant interest from Asian organizations. This interest is partly due to resveratrol’s use in Asian herbal medicines, recent patent approvals in Hong Kong and China, and China’s list of rare disease indications where JOTROL™ could be applicable. Additionally, recent publications in the Journal of Alzheimer’s Disease and AAPS Open, along with the projected growth of the Traditional Chinese Medicine market, have contributed to this interest. 19 The Company has entered service agreements with firms in Hong Kong to accelerate product development in Southeast Asia. These agreements aim to leverage local expertise and networks to facilitate market entry and potential out-licensing deals. The Company entered into an agreement with Dominant Treasure Health to expand its business development in China, Malaysia, and Singapore, aiming to penetrate the large and challenging Asian market. In March 2025, the Company unveiled a new strategic initiative to introduce Nugevia—a consumer-oriented product line dedicated to longevity and wellness. This initiative aims to meet the rising demand for scientifically backed wellness solutions by developing nutritional products that support both longevity and health span. Positioned within a rapidly growing global industry expected to reach $8.0 trillion by 2030, Nugevia products will leverage Jupiter’s proprietary JOTROL™ technology, a resveratrol-based platform that is designed to deliver an increase in the bioavailability profile of resveratrol. The first products under the Nugevia brand, focusing on supporting longevity and health span are available for sale and shipments began in the fourth quarter of 2025 through a direct-to-consumer model. The products are: ● Nugevia GLO (“GLO”), which helps promote and support cellular functions and skin vitality; ● Nugevia MND (“MND”), which supports cognitive resilience; and ● Nugevia PWR (“PWR”), which helps support mitochondrial function, which is a key for sustained growth and performance. The three debut formulations—GLO, MND, and PWR—are designed to support wellness and longevity through intelligent stacking of synergistic ingredients, all enhanced for optimal absorption via the JOTROL™ system. The Company plans to market these products in the U.S. and internationally. Nugevia’s launch is a pivotal move to monetize Jupiter’s proprietary science, support ongoing clinical trials, and capture a share of the booming longevity market. The Company operates through two segments: (i) the sale of premium nutritional supplements under the Nugevia brand, and (ii) pharmaceutical operations centered on the development of drug candidates. Financial Position For the three months ended March 31, 2026 and 2025, we generated net revenues of $18,652 and $0, respectively from product sales and reported net losses of $2,061,958 and $1,528,867, respectively, and negative cash flow from operating activities of $1,432,100 and $1,063,041, respectively. As noted in our financial statements, as of March 31, 2026 and December 31, 2025, we had an accumulated deficit of $36,728,984 and $34,667,026, respectively. There is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative cash flows from operations as well as our dependence on private equity and financings. See “Risk Factors” included herein and in our Annual Report on Form 10-K for additional discussion of risks associated with our capital requirements. Components of Results of Operations Research and Development Expenses Research and development expense reflects costs to advance our pharmaceutical programs and support product development for our consumer health initiatives. Key drivers include third-party service agreements to accelerate development and distribution efforts in Asia and program-level activities such as procurement of clinical trial supplies. We expense research and development expenses as incurred, and certain multi-period service arrangements are recognized ratably over their terms, which can create period-to-period variability as new agreements commence or milestones occur. 20 General and Administrative Expenses General and administrative expense comprises corporate overhead necessary to operate as a public company and to support our dual focus on pharmaceuticals and premium nutritional supplements. Major components include personnel-related costs, professional fees (legal, accounting, regulatory, commercialization support), facilities and insurance, and other public-company compliance costs. Fluctuations versus prior periods primarily reflect changes in staffing, stock-based compensation, external advisory needs, and launch-readiness activities for the consumer health business. Interest Income Interest income is generated from cash and cash equivalents, with period-to-period changes driven by average cash balances and prevailing short-term yields. The timing of capital raises, and operating cash usage can influence both the absolute level of interest income and its variability across reporting periods. Our policy treats highly liquid investments with original maturities of three months or less as cash equivalents. Interest Expense Interest expense primarily arises from financing arrangements recorded on our balance sheet (including notes payable), and will vary based on outstanding principal, effective interest rates, and any amortization of related financing costs. Changes in borrowings or the terms of such obligations can therefore impact period-over-period comparability. Results of Operations Three Months Ended March 31, 2026 Compared to the Three Months Ended March 31, 2025 The period-to-period comparisons of our historical results are not necessarily indicative of the results that may be expected in the future. The results of operations for the three months ended March 31, 2026 and March 31, 2025, have been derived from the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. For the Three Months Ended Variance March 31, 2026 March 31, 2025 March 31, 2026 March 31, 2025 Expenses: Research and development $ 411,049 $ 466,745 $ (55,696 ) (12 )% General and administrative 1,566,241 1,071,258 494,983 46 % Total operating expenses 1,977,290 1,538,003 439,287 29 % Loss from operations (1,963,000 ) (1,538,003 ) (424,997 ) 28 % Other Income (Expenses): Interest income 18,404 10,365 8,039 78 % Gain on change in fair value of convertible note 1,282 - 1,282 100 % Interest expense (118,644 ) (1,229 ) (117,415 ) 9554 % Gain on extinguishment of debt - - Other income - - Total other income (expenses), net (98,958 ) 9,136 (108,094 ) (1,183 )% Net (loss) income $ (2,061,958 ) $ (1,528,867 ) $ (533,091 ) 35 % Research and Development Expenses Research and development (“R&D”) expenses were $411,049 for the three months ended March 31, 2026 compared to $466,745 for the three months ended March 31, 2025, representing a decrease of $55,696, or 12%. The decrease in R&D expenses was primarily attributable to reductions of $54,114 in clinical trial expenses, $37,231 in payroll and consulting expenses, and $1,622 in other expenses, partially offset by an increase of $6,026 in expenses related to meetings and conferences. 21 General and Administrative Expenses General and administrative expenses were $1,566,241 for the three months ended March 31, 2026 compared to $1,071,258 for the three months ended March 31, 2025, representing an increase of $494,983, or 46%. The increase was primarily attributable to increases of $217,899 in payroll and consulting expenses, $184,825 in expenses related to Nugevia, $83,382 in investor and public relations expenses, and $5,316 in other expenses. Interest Income Interest income was $18,404 for the three months ended March 31, 2026, compared to $10,365 for the three months ended March 31, 2025, representing an increase of $8,039, or 78%. The increase was primarily attributable to higher average cash balances in interest-earning accounts during the three months ended March 31, 2026. Interest Expense Interest expense was $118,644 for the three months ended March 31, 2026, compared to $1,229 for the three months ended March 31, 2025, representing an increase of $117,415, or 9,554%. The significant increase in the current period reflects the interest related to the Convertible Notes. Gain on Change in Fair Value of Convertible Note The Company recognized a $1,282 gain from marking to market the Convertible Notes during the three months ended March 31, 2026. Liquidity and Capital Resources; Plan of Operations As of March 31, 2026, we had cash and cash equivalents of $2,362,749. Our cash equivalents are held in high yield savings account. Since inception, we have incurred net losses and negative cash flows from operations. On March 31, 2026, we had an accumulated deficit of $36,728,984. Historically, we have financed our operations primarily by selling common stock and convertible debt. On October 24, 2025, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) and related Registration Rights Agreement with YA II PN, Ltd. (“Yorkville”), providing the Company the right, but not the obligation, to sell up to $20.0 million of common stock from time to time, subject to customary conditions, including an effective resale registration statement. In connection with the SEPA, Yorkville agreed to provide $6.0 million of pre-paid advances via convertible promissory notes. During the year ended December 31, 2025, the company received aggregate proceeds of $5,100,000, which is net of $420,000 of issuance discounts and $480,000 of financing costs associated with the transaction. During the three months ended March 31, 2026, the Company received aggregate proceeds of $603,854 from sales of common stock under the SEPA which were used to pay interest on the convertible promissory notes. On December 2, 2024, the Company priced its initial public offering of 2,750,000 shares of common stock at a price of $4.00 per share. The offering closed on December 4, 2024, and the Company started trading on the Nasdaq Capital Market under the ticker symbol “JUNS”. The Company sold 2,750,000 shares of its Common Stock to the underwriters and yielded proceeds of $9,725,213, net of underwriters and other fees of $1,274,787. For the three months ended March 31, 2026 and 2025, we generated net revenues of $18,652 and $0, respectively from product sales and reported net losses of $2,061,958 and $1,528,867, respectively, and negative cash flow from operating activities of $1,432,100 and $1,063,041, respectively. As noted in our financial statements, as of March 31, 2026 and December 31, 2025, we had an accumulated deficit of $36,728,984 and $34,667,026, respectively. There is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative cash flows from operations as well as our dependence on private equity and financings. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including: ● the scope, rate of progress and costs of our drug delivery, preclinical development activities, laboratory testing and clinical trials for our drug candidate; ● the number and scope of clinical programs we decide to pursue; ● the scope and costs of manufacturing development and commercial manufacturing activities; 22 ● the extent to which we acquire or in-license other drug candidates and technologies; ● the cost, timing and outcome of regulatory review of our drug candidate; ● the cost and timing of establishing sales and marketing capabilities, if our drug candidate receives marketing approval; ● the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; ● our ability to establish and maintain collaborations on favorable terms, if at all; ● our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our drug candidate; ● the amount of profit, if any, generated from the sales of the Nugevia product line; ● the costs associated with being a public company; and ● the cost associated with commercializing our drug candidate, if it receives marketing approval. See “Risk Factors” included herein and in our Annual Report on Form 10-K for additional discussion of risks associated with our capital requirements. Cash Flows for the Three months ended March 31, 2026 and 2025 The following table shows a summary of our cash flows for the three months ended March 31, 2026 and 2025. For the Three months ended March 31, 2026 2025 Net cash flows used in operating activities $ (1,432,100 ) $ (1,063,041 ) Net cash flows from investing activities - - Net cash flows from financing activities $ 5,507 $ - Net increase (decrease) in cash $ (1,426,593 ) $ (1,063,041 ) Net Cash Flows From Operating Activities: Net cash used in operating activities during the three months ended March 31, 2026 was $1,432,100, as compared to net cash used in operating activities of $1,063,041 for the three months ended March 31, 2025. The increase in net cash used in operating activities was primarily attributable to the significant increase in net loss, which totaled $2,061,958 for the three months ended March 31, 2026 compared to $1,528,867 for the three months ended March 31, 2025. The higher net loss was partially offset by increased non-cash adjustments, including $500,992 of stock-based compensation for the three months ended March 31, 2026 compared to $421,454 for the three months ended March 31, 2025 and $131,479 of interest paid by stock in the three months ended March 31, 2026, which did not occur in the prior period. Additionally, the current period included a $1,282 gain on the change in fair value of convertible notes, which did not recur in the prior period. Changes in working capital also contributed to the variance, primarily due to an increase in accounts payable and accrued expenses of $162,136 as of March 31, 2026 compared to $113,552 as of March 31, 2025 and an increase of $25,255 in accrued compensation as of March 31, 2026 versus a decrease of $7,435 as of March 31, 2025 Net Cash Flows From Financing Activities: For the three months ended March 31, 2026, net cash provided by financing activities consisted of proceeds from the exercise of stock options of $5,507. For the three months ended March 31, 2025, there were no cash flows from financing activities. Off-balance sheet financing arrangements We have no obligations, assets or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets. 23 We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors. Asian Business Development Activities The Company initiated business development activities in the Asian region beginning in October of 2021. The Company has a strong strategic interest in accelerating the drug development and potential commercialization efforts of JOTROL™ in this market. Our Chairman & CEO, Christer Rosén, presented in person, our company’s status and pipeline at the BIOHK 2023 in Hong Kong in September of 2023. The presentation led to several follow-on meetings, and we have recently agreed to service agreements in the areas of business development, CMC (Chemistry, Manufacturing, and Controls), regulatory affairs and clinical trial management. These agreements are further described in the section “Other Material Agreements”. The Asian market is very large and hard to penetrate for a small company and we believe that our strategy with these agreements is cost effective and have the possibility to accelerate an out-licensing deal in the Southeast Asian territories. However, there are no assurances that this approach will be successful. The agreements executed are very similar in nature that include an equity investment in our company by the other party and in turn the Company issued equity in form of shares of common stock, in lieu of cash, for 3 years of services from each company. The Company believes these agreements to be favorable for both parties based on the cash position of the company and the need for these activities to be executed and enabling the possibility of a one or more out-licensing agreements in the territory. Notes Payable to Related Parties and Other Transactions As of March 31, 2026 and December 31, 2025, $84,105 and $64,105, respectively, were payable to Titan Advisory Services LLC (“Titan”), a company wholly owned by the Company’s Chief Financial Officer, pursuant to a Master Services Agreement (“MSA”) dated December 31, 2022. Under the MSA, Titan provides executive finance and corporate support services to the Company, including services by Saleem Elmasri as Chief Financial Officer. Critical Accounting Policies Our accounting policies are more fully described in Note 2 - Significant accounting policies to our consolidated financial statements included as part of this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K. 24 ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. Not applicable. ITEM 4. CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer (our “Certifying Officers”), the effectiveness of our disclosure controls and procedures as of March 31, 2026, pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of March 31, 2026, our disclosure controls and procedures were ineffective due to a deficiency in our ability to adequately segregate responsibility over financial transaction processing and reporting. Based on the number of personnel available to serve the Company’s accounting function, management believes we are not able to adequately segregate responsibility over financial transaction processing and reporting. Further, the Company does not have a formal internal control environment in place and operating effectively. As such, we have identified these issues as material weaknesses in our internal control over financial reporting and we may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If our remediation of such material weaknesses is not effective, or if we fail to develop and maintain an effective system of internal controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable laws and regulations could be materially and adversely affected and the market price of our common stock could be negatively affected, which could require additional financial and management resources. We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 25 PART II - OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to, among other things, intellectual property, commercial arrangement, employment, and regulatory matters. While the outcome of these proceedings and claims cannot be predicted with certainty, as of March 31, 2026, we were not party to any material legal or arbitration proceedings. No governmental proceedings are pending or, to our knowledge, contemplated against us. ITEM 1A. RISK FACTORS Please carefully consider the information set forth in this Quarterly Report on Form 10-Q, and the risk factors discussed in Part I, “Item 1A. Risk Factors” of our Annual Report on Form 10-K, which could materially affect our business, financial condition, or future results. Any of the risk factors contained in our Annual Report on Form 10-K, as well as additional risks and uncertainties not presently known to us or that we currently deem immaterial, could materially affect our business, results of operations, and financial condition or future results, which in turn could materially and adversely affect the trading price of shares of our Common Stock. As of the date of this Quarterly Report on Form 10-Q, there have been no material updates or changes with respect to the risk factors previously disclosed in our Annual Report on Form 10-K. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Note 6 to the condensed consolidated interim financial statements included in Item 1 of this Quarterly Report is incorporated by reference herein. ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. ITEM 4. MINE SAFETY DISCLOSURES Not applicable. ITEM 5. OTHER INFORMATION Trading Arrangements During the three months ended March 31, 2026, no director or officer of the Company adopted , modified , or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408(a) of Regulation S-K. 26 ITEM 6. EXHIBITS Exhibit No. Descriptio n 4.1 Omnibus Amendment to the Convertible Promissory Notes issued to YA II PN, Ltd., dated February 20, 2026, between Jupiter Neurosciences, Inc. and YA II PN, Ltd. (incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 27, 2026) 31.1* Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act* 31.2* Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act* 32.1* Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act** 32.2* Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act** 101.INS* Inline XBRL Instance Document* 101.SCH* Inline XBRL Taxonomy Extension Schema Document* 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document* 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document* 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document* 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document* 104* Cover Page Interactive Data File (embedded within the Inline XBRL document)* * Filed herewith. ** Furnished herewith. 27 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Jupiter Neurosciences, Inc. Date: May 14, 2026 /s/ Christer Rosén Christer Rosén Chief Executive Officer (Principal Executive Officer) Date: May 14, 2026 /s/ Saleem Elmasri Saleem Elmasri Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) 28